Unaltered NKG2D-CAR T cell function under hypoxia in osteosarcoma in vitro.

Area of Science:

• Oncology
• Immunology
• Biomedical Research

Background:

• Osteosarcoma (OS) is a prevalent pediatric bone cancer with poor survival rates for relapsed or metastatic cases.
• Immunotherapy, particularly chimeric antigen receptor (CAR) T cells, shows promise for OS treatment.
• The tumor microenvironment (TME), especially hypoxia, is a known barrier to effective immunotherapy.

Purpose of the Study:

• To investigate the impact of hypoxia on NKG2D-CAR T cell function in osteosarcoma.
• To determine if hypoxia contributes to the suppressive TME observed in OS xenograft models.

Main Methods:

• In vitro osteosarcoma models were used to assess hypoxia's effects.
• Expression of HIF-1α, NKG2D ligands, and immune checkpoints were analyzed.
• Functional assays evaluated NKG2D-CAR T cell phenotype, activity, and cytokine secretion under hypoxic conditions.

Main Results:

• Hypoxia did not reduce NKG2D ligand expression or alter immune checkpoint profiles.
• NKG2D-CAR T cell phenotype, activity, and cytokine secretion remained unaffected by hypoxia in vitro.
• CAR T cell efficacy against 3D osteosarcoma spheroids was preserved under hypoxic conditions.

Conclusions:

• Hypoxia alone does not compromise in vitro NKG2D-CAR T cell efficacy in osteosarcoma.
• Further research is needed to understand how hypoxia interacts with other TME factors to modulate CAR T cell behavior.